Diabetes Care Market Scenario of India


Diabetes has become a major health care problem in India. The rising burden of diabetes has greatly affected the health care sector and economy in India.

India currently represents 49% of the world’s diabetes burden, with an estimated 72 million cases in 2017, a figure expected to almost double to 134 million by 2025.

Considering the above facts Hospaccx team started working the mapping of market trends and dynamics. This is microficial study of diabetic market if you want to get into more detail you can contact [email protected]


  • The number of people with diabetes has risen from 108 million in 1980 to 422 million in 2014.
  • The global prevalence of diabetes among adults over 18 years of age has risen from 4.7% in 1980 to 8.5% in 2014.
  • Diabetes prevalence has been rising more rapidly in middle- and low-income countries.
  • Diabetes is a major cause of blindness, kidney failure, heart attacks, stroke and lower limb amputation.
  • Almost half of all deaths attributable to high blood glucose occur before the age of 70 years. WHO projects that diabetes will be the seventh leading cause of death in 2030.
  • With 69.1 million suffering from diabetes, India continues to be the ‘diabetes capital’.
  • In India,type 2 diabetes makes up about 85-90% of all cases.
  • Deaths due to diabetes increased 50% in India between 2005 and 2015, and are now the seventh most common cause of death in the country, up from the 11th rank in 2005.
  • There are 69.1 million people with diabetes in India, the second highest number in the world after China, which has 109 million people with diabetes. Of these, 36 million cases remain undiagnosed.



  • Diabetes is one of the first diseases described with an Egyptian manuscript from  1500 BCE mentioning “too great emptying of the urine.”
  • The first described cases are believed to be of type 1 diabetes.
  • Indian physicians around the same time identified the disease and classified it as madhumeha or honey urine noting that the urine would attract ants.
  • The term “diabetes” or “to pass through” was first used in 250 BC by the Greek Apollonius of Memphis.
  • Type 1 and type 2 diabetes were identified as separate conditions for the first time by the Indian physicians Sushruta and Charaka in 400-500 CE with type 1 associated with youth and type 2 with obesity.
  • The term “mellitus” or “from honey” was added by Thomas Willis in the late 1600s to separate the condition from diabetes insipidus which is also associated with frequent urination.
  • The discovery of a role for the pancreas in diabetes is generally ascribed to Joseph von Mering and Oskar Minkowski, who in 1889 found that dogs whose pancreas was removed developed all the signs and symptoms of diabetes and died shortly afterwards.
  • In 1910, Sir Edward Albert Sharpey-Schafer suggested that people with diabetes were deficient in a single chemical that was normally produced by the pancreas—he proposed calling this substance ‘insulin’.
  • Banting, Best, and colleagues (especially the chemist Collip) went on to purify the hormone insulin from bovine pancreases at the University of Toronto. This led to the availability of an effective treatment—insulin injections—and the first patient were treated in 1922.
  • The distinction between what is now known as type 1 diabetes and type 2 diabetes was first clearly made by Sir Harold Percival (Harry) Himsworth, and published in January 1936.
  • Identification of the first of the sulfonylureas in 1942
  • Reintroduction of the use of biguanides for Type 2 diabetes in the late 1950s. The initial phenformin was withdrawn worldwide (in the U.S. in 1977) due to its potential for sometimes fatal lactic acidosis and metformin was first marketed in France in 1979, but not until 1994 in the US.
  • Identification of the first thiazolidinedione as an effective insulin sensitizer during the 1990s
  • In 2005, a new drug to treat type 2 diabetes, derived from the Gila monster was approved by the Food and Drug Administration. The venom of the lizard contains exendin 4, which triggers one of the insulin-releasing pathways.


1. Indian surgeon claims surgical cure for diabetes

Dr Shashank Shah, a Pune-based bariatric surgeon, claims to have discovered a surgical cure for type II diabetes, and boasts of an impressive 90% success rate.

The Cleveland Clinic, one of the world’s foremost hospitals, has sponsored an interaction between Dr Shah and 250 of America’s top doctors, diabetologists and endocrinologists

2. Herbal composition

Suresh Sharma of Jaipur who invented the formula for diabetes cure from Cadambine and dihydrocinchnine alkaloids derived from kadamb leaves. Mr. Sharma had tested the medicine on over 1,000 patients besides himself. The results were positive and there were no side-effects. In the case of chronic diabetic patients one tablet a week for 4-10 months had brought about the result while in beginners medication was required only once a month.

3. Artificial pancreas

Dr. Satish Garg predicts that the artificial pancreas will be complete in five years. The artificial pancreas is actually a combination of the insulin pump and sensor. The part that has been approved so far, does the task of keeping a watch on the blood glucose, and when it senses a drop, it immediately sends a message to the pump to suspend insulin supply. This way, patients can avoid episodes of hypoglycaemia. The second innovation is for the sensor to tell the pump to speed up when sugars are high, but this is yet to be approved.

4. The sweet switch

Dr Surendra Ugale of Kirloskar Hospital in Hyderabad and Dr Ramen Goel of Bombay Hospital tried out through the Ileal Transposition (or small intestinal switch). The procedure shortens the intestinal tract between the stomach and terminal ileum, shifts it into an upper area and puts it in line again. A biochemical process that facilitates insulin secretion in the presence of undigested food and controls Type II diabetes-a metabolic disorder that is marked by the failure to absorb sugar and starch due to lack of the hormone insulin.


Diabetes Alert

  • The overall prevalence of diabetes in India is 7·8%.
  • The prevalence of diabetes varies from 4·3% in Bihar to 10·0% in Punjab and is higher in urban areas (11·2%) than in rural areas (5·2%) and higher in mainland states (8·3%) than in the northeast (5·9%).
  • States with higher per-capita GDP seemed to have a higher prevalence of diabetes (eg, Chandigarh, which had the highest GDP of US$ 3433, had the highest prevalence of 13·6%, 12.8–15·2).
  • In rural areas of all states, diabetes is more prevalent in individuals of higher socioeconomic status.
  • However, in urban areas of some of the more affluent states (Chandigarh, Maharashtra, and Tamil Nadu), diabetes prevalence is higher in people with lower socioeconomic status.
  • The overall prevalence of pre-diabetes is 10·3%.
  • The prevalence of pre diabetes varied from 6·0% in Mizoram to 14·7% in Tripura, and the prevalence of impaired fasting glucose is generally higher than the prevalence of impaired glucose tolerance.


  • Going by current treatment costs, India’s total bill for treating diabetes would be US$30 billion by 2025
  • But with economic growth and standards of care improving, treatment costs are likely to rise, and it has estimated the same cost to go up to US$79.7 billion.
  • The per person annual cost of managing diabetes in India is Rs 25,000 approximately. There will be a wide variation based on complications, etc.
  • It is estimated that diabetes patients in urban areas spend Rs 10,000 and patients in rural areas spend Rs 6,260 every year on treatment.
  • Since most of the healthcare cost is borne out of pocket in India, those in lower economic groups have to bear the greatest burden. Urban poor spend as much as 34% while rural poor spend 27% of their income on diabetes treatment.


Population-wide policies and initiatives such as marketing restrictions on unhealthy foods and non-alcoholic beverages to children, nutrition labelling, food taxes and subsidies, physical activity policies and social marketing campaigns are typically designed to alter the food and physical activity environments to make healthier choices the easier choices for individuals within the population.

In an effort to curb the growing incidence of diabetes in India, the government is planning stringent measures including higher taxes and stricter advertisement norms to regulate sale of sugar-sweetened beverages and junk food in the country.

The National Agricultural Policy encourages the development of strategies to ensure that fruit and vegetables are accessible to poorer populations. So, population eats healthy and avoid junk foods.

The National Urban Renewal Mission (NURM), launched in 2005, gives the central government priority to construct bicycle lanes and pedestrian paths. To avoid physical inactivity and encourage walking, cycling of the population.

Nutrition labelling

In India, FSSAI provides regulations for processed foods to display nutrition information on the product packaging, including levels of energy, protein, total fat, saturated fat, carbohydrate, sugars and sodium. This provides an opportunity for introducing such interpretative labelling for prevention of diabetes and other NCDs.

Social marketing for awareness generation

Social marketing campaigns using paid and non-paid forms of media across multiple channels are considered cost effective for improving diets and promoting physical activity.


The global market of diabetic drugs is on the rise owing to the spike in the number of cases of diabetes – both type 1 and type 2. As per a recent report by WHO, around 422 million people worldwide suffer from diabetes. Diabetes of any kind can result in complications in many parts of the body and also up the risk of premature death. According to findings of WHO, in 2012 it claimed around 1.5 million lives all over the world.

The market size in 2017 for Global diabetes market was registered to be 56154.80 USD million and expected a CAGR of 6.25% during the forecast period 2018-2023.

Approximately 10% of all diabetes cases are type 1 and approximately 90% of all cases of diabetes worldwide are of this type.

The rising prevalence of diabetes in the United States is the most influencing factor driving the market for diabetes drugs. As of 2017, 24.186 million people are diabetic that attributes to 7.4% of the United States population. Statistics prove that 1 in 10 individuals in the country has diabetes and a rise in this trend is expected to take the situation to 1 in 3 by 2050.

Diabetes patients

Leading cause of death globally


  • In an indicator of the growing prevalence of diabetes in India, the domestic diabetes drugs market for FY’12 grew 22 per cent at $700 million.

(Credit Suisse report)

  • The pharmaceutical industry is witnessing 25% growth in overall diabetes and 15% in insulin segment
  • The overall anti-diabetes market in India was worth $680.3m in 2011 and is projected to grow at a CAGR of 11.3% between 2011 and 2018 to reach $1,446m in 2018.
  • Anti-diabetes therapeutic segment is the second fastest growing segment, after oncology.
  • The demand for drugs in ‘pharmerging’ markets will expand at a compound annual growth rate of as much as 11% and account for nearly 50% of absolute growth in drugs spending in 2018


  • Price regulation in insulin market in India.
  • Use of complementary and alternative diabetes medicines.
  • Compulsory Licensing & Patent revocation of Drugs or Formulations in India.
  • Increasing cost of launching new drugs and patent expiries of Drugs.
  • Developing new ant diabetes drugs.


  • Increase in the number of diabetic population in India.
  • Comprehensive health insurance policies covering diabetes.
  • Increasing aging population.


1. Dr. Mohan Diabetes Specialities Centre- Delhi

It was established on 1st September 1991, a centre of excellence for diabetes care and research in the heart of Chennai. Within a span of 25 years, Dr. Mohan’s DSC has blossomed into an international centre of excellence in diabetes.

2. Life Span Diabetes Clinics- Kolkata

India’s First and Largest Chain of Diabetes Clinic. It’s a caring endeavour founded by Ashok Jain, who is a diabetic himself for 21 years. With 40 Clinics across 10 cities, we have already reached out to help 81,000 diabetics.

3. Apollo Sugar Clinic- Raipur

Apollo Sugar Clinics is an innovative, single speciality diabetes and endocrine healthcare service provider, formed as collaboration between Apollo Health & Lifestyle and Sanofi. This proven model of success aims to provide accessible care for diabetes and continues to expand its network across India.

4. Chellaram Diabetes Institute (CDI) – Pune

It is a unit of The Chellaram Foundation, is a Not-for-Profit Institute based in Pune. Chellaram Diabetes Institute, with advanced Research, Education, Awareness, Medical and Diagnostic facilities, is geared to create an impact on the alarming Diabetes scenario, by providing unique and state-of-the-art services under one roof.

5. M.V. Hospital for Diabetes situated at Royapuram- Chennai

It was established by late Prof. M. Viswanathan, Doyen of Diabetology in India in 1954 as a general hospital. In 1971 it became a hospital exclusively for diabetes care. It has, at present, 100 beds for the treatment of diabetes and its complications.

6. Diabetacare – Bangalore

Partnering above 65 clinics spread globally, Diabetacare has a history of successfully serving over 30 thousand customers. Offer counselling for both pre & post diabetic patients helping them understand and evaluate the seriousness of their condition.

7. Niramay Diabetes Super Speciality Centre- Mumbai


  • With the increasing burden of diabetes in India, it is essential to provide the comparable facilities and resources to tackle the diseases.
  • Increasing population of diabetes, also increases the diabetes related problems i.e. kidney, eyes and etc.This increases the morbidity and mortality which has the strong impact on the economy of the country.
  • As per the report, India lacks 6 health workers per 10,000 people.
  • Though there are many government policies and programmes in India to control and prevent diabetes but unawareness regarding the diseases was noted in large population especially in rural.
  • Looking at the estimated figure of the diabetes population in the coming years, India needs diabetic care centres and healthcare workers to provide the required diabetic care to the population.

Are you planning to build or restructure or venture in Diabetes Centre or Hospital in India? Looking for information about the major healthcare players in Government, Private diagnostic centers that are available in India? Are you looking to find out which part of the city’s is best to venture in or what all facilities are available and what all should be planned for new setup? In this article Hospaccx Healthcare Consultancy has mapped all on major players in terms of Diabetes facilities and healthcare scenario in India.

Below is the superficial and macro level survey if you need a refined market and financial feasibility or any other study related to healthcare is required you can contact Hospaccx Healthcare business consulting Pvt. ltd on [email protected] or [email protected] Or you can visit our website on www.hhbc.in

Please follow and like us: